Current Affairs - Business - Discussion

Cipla has launched Yurpeak, a tirzepatide-based injectable designed for weekly use to help manage both obesity and type-2 diabetes. This development follows regulatory approval for the underlying molecule and positions Cipla as the distributor and promoter of the second tirzepatide brand available in India. The introduction of this therapy is significant because metabolic disorders such as obesity and diabetes are rapidly increasing across the country. By offering advanced treatment options, Cipla aims to support improved clinical outcomes, enhance patient access to cutting-edge therapies, and contribute to addressing India’s pressing public health challenges.